Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vytorin Gets Medical Group Support, Congressional Query On ENHANCE

Executive Summary

Merck/Schering-Plough's Vytorin has drawn support from major medical groups as it faces a new Congressional inquiry and possible legal action in the wake of unfavorable study results from the much-anticipated ENHANCE trial

You may also be interested in...



Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review

Three of the leading Medicare Part D sponsors will not cover Merck/Schering-Plough's Vytorin in their stand-alone drug plans in 2009, and much of the blame can probably be laid on the disappointing results of the ENHANCE study earlier this year

Vytorin Won’t Be ENHANCEd By Part D In 2009: Formulary Review

Three of the leading Medicare Part D sponsors will not cover Merck/Schering-Plough's Vytorin in their stand-alone drug plans in 2009, and much of the blame can probably be laid on the disappointing results of the ENHANCE study earlier this year

Rep. Dingell’s Prescription For DTC Offered To Pharma Panel At Hearing

House Energy and Commerce Committee Chairman John Dingell, D-Mich., outlined several precepts for enhancing direct-to-consumer drug advertising at a May 8 hearing by the Energy and Commerce Oversight and Investigations Subcommittee

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel